Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Abstract Background Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the t...

Full description

Bibliographic Details
Main Authors: Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
Advanced breast cancer
Metastatic
Antihormone therapy
Heregulin
Seribantumab
MM-121
Online Access:http://link.springer.com/article/10.1186/s12885-020-07546-1

Internet

http://link.springer.com/article/10.1186/s12885-020-07546-1

Similar Items